Dual Energy X-ray Absorptiometry (DXA) Comparison Hip Resurfacing Versus Total Hip Arthroplasty (THA)

NCT ID: NCT01359527

Last Updated: 2019-04-26

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 31 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2008-12-31
• Study Completion Date: 2018-11-30

Brief Summary

This study compares the change (loss) of bone mineral density (BMD) that occurs in the proximal femur after hip resurfacing and total hip replacement.

Detailed Description

This study compares the change (loss) of bone mineral density (BMD) that occurs in the proximal femur after hip resurfacing and total hip replacement. The goal is to evaluate the bone loss in the proximal femur resulting from hip resurfacing surgery and to compare this to the bone loss in the proximal femur resulting from total hip arthroplasty.

Conditions

Osteoarthritis, Hip

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Hip Resurfacing

Hip Resurfacing

Intervention Type: DEVICE

Total Hip Arthroplasty

Total Hip Arthroplasty

Intervention Type: DEVICE

Interventions

Hip Resurfacing

Intervention Type: DEVICE

Total Hip Arthroplasty

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age of at least 20 years
• Osteoarthritis
• Elective Total Hip Arthroplasty / Resurfacing
• Signed Informed Consent

Exclusion Criteria

• Osteoporosis
• Revisions
• Femoral dysplasia
• Trochanteric osteotomy
• Inflammatory arthritis
• Breast-feeding, pregnancy, or women of child-bearing potential without documentation of a negative pregnancy test and not utilizing contraception
• Patients with a history of having taken or currently taking PTH, fluoride therapy or strontium ranelate or patients taking other chronic medications that in the Investigator's opinion are known to affect bone mineral density in a substantial way
• Patients with severe medical condition(s) that in the view of the Investigator prohibits participation in the study
• Use of any other investigational agent in the last 30 days

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Spokane Joint Replacement Center

OTHER

Sponsor Role: lead

Responsible Party

David F. Scott, MD

PI

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

David Scott, MD

Role: PRINCIPAL_INVESTIGATOR

Spokane Joint Replacement Center

Locations

Spokane Joint Replacement Center

Spokane, Washington, United States

Countries

United States

Other Identifiers

SJRC-RSRF

Identifier Type: -

Identifier Source: org_study_id